"Mifepristone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.
| Descriptor ID |
D015735
|
| MeSH Number(s) |
D04.210.500.365.415.580
|
| Concept/Terms |
R-38486- R-38486
- R 38486
- RU-486
- RU 486
- RU486
- R38486
- RU-38486
- RU 38486
- RU38486
|
Below are MeSH descriptors whose meaning is more general than "Mifepristone".
Below are MeSH descriptors whose meaning is more specific than "Mifepristone".
This graph shows the total number of publications written about "Mifepristone" by people in this website by year, and whether "Mifepristone" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Mifepristone" by people in Profiles.
-
Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells. PLoS One. 2012; 7(1):e29021.
-
LAT1 regulates growth of uterine leiomyoma smooth muscle cells. Reprod Sci. 2010 Sep; 17(9):791-7.
-
Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res. 2010 Feb 15; 70(4):1722-30.
-
A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2010 Mar; 116(3):332-4.